Literature DB >> 23288666

Predictive socioeconomic and clinical profiles of antidepressant response and remission.

Felipe A Jain1, Aimee M Hunter, John O Brooks, Andrew F Leuchter.   

Abstract

BACKGROUND: There are many prognostic factors for treatment outcome in major depressive disorder (MDD). The predictive power of any single factor, however, is limited. We aimed to develop profiles of antidepressant response and remission based upon hierarchical combinations of baseline clinical and demographic factors.
METHODS: Using data from Level 1 of the Sequenced Treatment Alternatives to Relieve Depression trial (STAR*D), in which 2,876 participants with MDD were treated with citalopram, a signal-detection analysis was performed to identify hierarchical predictive profiles for patients with different treatment outcome. An automated algorithm was used to determine the optimal predictive variables by evaluating sensitivity, specificity, positive and negative predictive value, and test efficiency.
RESULTS: Hierarchical combinations of baseline clinical and demographic factors yielded profiles that significantly predicted treatment outcome. In contrast to an overall 47% response rate in STAR*D Level 1, response rates of profiled patient subgroups ranged from 31 to 63%. In contrast to an overall remission rate of 28%, identified subsets of patients had a 12 to 55% probability of remission. The predictors of antidepressant treatment outcome most commonly incorporated into profiles were related to socioeconomic status (e.g., income, education), whereas indicators of depressive symptom type and severity, as well as comorbid clinical conditions, were useful but less powerful predictors.
CONCLUSIONS: Hierarchical profiles of demographic and clinical baseline variables categorized patients according to the likelihood they would benefit from a single antidepressant trial. Socioeconomic factors had greater predictive power than symptoms or other clinical factors, and profiles combining multiple factors were stronger predictors than individual factors alone.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  antidepressants; anxiety/anxiety disorders; clinical trials; depression, gender; pharmacotherapy; treatment

Mesh:

Substances:

Year:  2013        PMID: 23288666     DOI: 10.1002/da.22045

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  19 in total

1.  Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder.

Authors:  Arjun Athreya; Ravishankar Iyer; Drew Neavin; Liewei Wang; Richard Weinshilboum; Rima Kaddurah-Daouk; John Rush; Mark Frye; William Bobo
Journal:  IEEE Comput Intell Mag       Date:  2018-07-20       Impact factor: 11.356

2.  Effectiveness of antidepressants and predictors of treatment response for depressed HIV patients in Uganda.

Authors:  Victoria K Ngo; Glenn J Wagner; Noeline Nakasujja; Akena Dickens; Frances Aunon; Seggane Musisi
Journal:  Int J STD AIDS       Date:  2014-12-18       Impact factor: 1.359

3.  Predicting treatment outcome in depression: an introduction into current concepts and challenges.

Authors:  Nicolas Rost; Elisabeth B Binder; Tanja M Brückl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-19       Impact factor: 5.270

4.  Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes.

Authors:  Johannes Rentzsch; Mazda Adli; Katja Wiethoff; Ana Gómez-Carrillo de Castro; Jürgen Gallinat
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-20       Impact factor: 5.270

5.  Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment.

Authors:  S Alboni; R M van Dijk; S Poggini; G Milior; M Perrotta; T Drenth; N Brunello; D P Wolfer; C Limatola; I Amrein; F Cirulli; L Maggi; I Branchi
Journal:  Mol Psychiatry       Date:  2015-09-15       Impact factor: 15.992

Review 6.  Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder.

Authors:  R C Kessler; H M van Loo; K J Wardenaar; R M Bossarte; L A Brenner; D D Ebert; P de Jonge; A A Nierenberg; A J Rosellini; N A Sampson; R A Schoevers; M A Wilcox; A M Zaslavsky
Journal:  Epidemiol Psychiatr Sci       Date:  2016-01-26       Impact factor: 6.892

7.  Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.

Authors:  S Susan Hedayati; L Parker Gregg; Thomas Carmody; Nishank Jain; Marisa Toups; A John Rush; Robert D Toto; Madhukar H Trivedi
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

8.  The effects of co-morbidity in defining major depression subtypes associated with long-term course and severity.

Authors:  K J Wardenaar; H M van Loo; T Cai; M Fava; M J Gruber; J Li; P de Jonge; A A Nierenberg; M V Petukhova; S Rose; N A Sampson; R A Schoevers; M A Wilcox; J Alonso; E J Bromet; B Bunting; S E Florescu; A Fukao; O Gureje; C Hu; Y Q Huang; A N Karam; D Levinson; M E Medina Mora; J Posada-Villa; K M Scott; N I Taib; M C Viana; M Xavier; Z Zarkov; R C Kessler
Journal:  Psychol Med       Date:  2014-07-17       Impact factor: 7.723

9.  Major depressive disorder subtypes to predict long-term course.

Authors:  Hanna M van Loo; Tianxi Cai; Michael J Gruber; Junlong Li; Peter de Jonge; Maria Petukhova; Sherri Rose; Nancy A Sampson; Robert A Schoevers; Klaas J Wardenaar; Marsha A Wilcox; Ali Obaid Al-Hamzawi; Laura Helena Andrade; Evelyn J Bromet; Brendan Bunting; John Fayyad; Silvia E Florescu; Oye Gureje; Chiyi Hu; Yueqin Huang; Daphna Levinson; Maria Elena Medina-Mora; Yoshibumi Nakane; Jose Posada-Villa; Kate M Scott; Miguel Xavier; Zahari Zarkov; Ronald C Kessler
Journal:  Depress Anxiety       Date:  2014-01-14       Impact factor: 6.505

10.  Depression-related work disability: socioeconomic inequalities in onset, duration and recurrence.

Authors:  Jenni Ervasti; Jussi Vahtera; Jaana Pentti; Tuula Oksanen; Kirsi Ahola; Mika Kivimäki; Marianna Virtanen
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.